Methods for detecting Bordetella spp.

Specific oligonucleotide primers and probes enhance Bordetella detection sensitivity by forming fluorescent complexes, addressing the limitations of existing methods and enabling accurate identification of Bordetella species in unpurified samples.

JP7589434B2Active Publication Date: 2024-11-26TOYOBO CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2019199027
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2019-10-31
Publication Date
2024-11-26
Estimated Expiration
2039-10-31

AI Technical Summary

Technical Problem

Existing methods for detecting Bordetella pertussis and Bordetella parapertussis are inadequate in terms of sensitivity and specificity, particularly when using unpurified samples, leading to potential amplification inhibition and false positives.

Method used

The use of specific oligonucleotide primers and probes, designed to target Bordetella species with high identity to SEQ ID NOs 1 and 2, in combination with PCR and fluorescence quenching dyes, allows for sensitive detection of Bordetella bacteria without the need for extensive sample purification.

Benefits of technology

This method enables high-sensitivity detection of Bordetella pertussis and Bordetella parapertussis, even in the presence of sample impurities, by forming fluorescent complexes that can be monitored in real-time, thereby improving clinical diagnostic capabilities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007589434000002
    Figure 0007589434000002
  • Figure 0007589434000003
    Figure 0007589434000003
  • Figure 0007589434000004
    Figure 0007589434000004
Patent Text Reader

Abstract

To provide techniques to differentially detecting Bordetella bacteria.SOLUTION: Disclosed is a nucleic acid primer set for differentially detecting Bordetella bacteria, that comprises a nucleic acid primer (I) and a nucleic acid primer (II): (I) a nucleic acid primer having a base sequence corresponding to contiguous 15-30 bases in a base sequence having 90% or more identity with a base sequence of a certain sequence number; (II) a nucleic acid primer having a base sequence corresponding to contiguous 15-30 bases in a base sequence that is complementary to the base sequence having 90% or more identity with the base sequence of the certain sequence number.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an oligonucleotide for distinguishing and detecting Bordetella bacteria contained in a specimen sample. The present invention further relates to a method for detecting Bordetella bacteria contained in a specimen sample using the oligonucleotide, and a reagent / kit for use in the method. [Background technology]

[0002] Among the Bordetella bacteria, Bordetella pertussis in particular is the main causative agent of whooping cough, a highly contagious respiratory infection. Whooping cough is particularly likely to become severe and even fatal when it infects infants who have not been vaccinated with the triple vaccine. Recently, whooping cough in vaccinated adults due to weakened immune effects of the vaccine has become a problem. Since few such infected adults develop severe symptoms, they may not realize that they are infected with Bordetella pertussis, which can lead to the spread of infection and the source of infection for infants.

[0003] It is known that a portion of whooping cough (approximately 2-20%) is caused by Bordetella parapertussis. Although the symptoms of whooping cough caused by Bordetella parapertussis are typically milder than those caused by Bordetella pertussis, differential diagnosis based on clinical signs alone is difficult. It has been reported that known methods for detecting Bordetella pertussis may give false positives when Bordetella parapertussis is present in high concentrations (Non-Reference 1). Therefore, there is a strong need for a test method that can specifically distinguish Bordetella pertussis from Bordetella parapertussis and detect them simply, quickly, and with high sensitivity in clinical diagnosis.

[0004] Conventional methods for testing Bordetella spp. include culture testing, serological testing, and genetic testing. Culture testing has the problem that it is often difficult to isolate the bacteria. Serological testing requires paired sera for accurate diagnosis, but at present, paired sera cannot be obtained, and even if paired sera are obtained, diagnosis takes time. As a genetic test, a test using the LAMP (Loop-mediated Isothermal Amplification) method is known, but at present, it is a method for detecting only Bordetella pertussis, and since no internal control is incorporated in the reaction system to confirm whether nucleic acid amplification has been performed normally, it is difficult to judge if amplification inhibition occurs. A method for detecting Bordetella pertussis and Bordetella parapertussis using the PCR method has also been considered, but the sensitivity is still insufficient, and there is a disadvantage that it cross-reacts with other Bordetella pertussis and Bordetella parapertussis bacteria other than Bordetella pertussis (Non-Patent Document 1).

[0005] Furthermore, as an example of a method using genetic testing, since Bordetella pertussis is one of the bacteria that cause respiratory infections, methods have been proposed to detect it in a manner that distinguishes it from other respiratory infections such as Mycoplasma pneumonia and Chlamydia pneumonia (e.g., Patent Document 1 and Patent Document 2).

[0006] In addition, methods for distinguishing and detecting Bordetella pertussis and Bordetella parapertussis have been proposed (e.g., Patent Document 3). However, there is a need for the development of a more useful method for distinguishing and detecting Bordetella bacteria with higher sensitivity. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Patent No. 6254085 [Patent Document 2] Patent No. 4503844 [Patent Document 3] JP 2014-230511 A [Non-patent literature]

[0008] [Non-Patent Document 1] In Vitro Diagnostic Medical Device FilmArray Respiratory Panel Package Insert (2nd Revised Edition, February 2019), bioMérieux Japan Co., Ltd. Summary of the Invention [Problem to be solved by the invention]

[0009] The present invention has been made against the background of the problems of the conventional technology. That is, an object of the present invention is to provide a method for easily and sensitively detecting Bordetella bacteria contained in a specimen sample. The present inventors have repeatedly studied conventionally known methods for distinguishing and detecting Bordetella pertussis and Bordetella parapertussis, and have found that when a sample with insufficient nucleic acid purification is used, this method is susceptible to amplification inhibition due to the influence of substances contained in the specimen sample, and may not be able to detect accurately. Therefore, an object of the present invention is to provide a new method for easily and sensitively distinguishing and detecting Bordetella bacteria even when a sample with insufficient nucleic acid purification is used. [Means for solving the problem]

[0010] As a result of intensive research, the present inventors discovered that Bordetella bacteria contained in a specimen can be detected easily and sensitively by using a specific oligonucleotide, and thus arrived at the present invention. That is, the outline of the present invention is as follows.

[0011] [Item 1] A nucleic acid primer set for distinguishing and detecting Bordetella genus bacteria, comprising a nucleic acid primer corresponding to the following (I) and a nucleic acid primer corresponding to the following (II): (I) a nucleic acid primer consisting of a nucleotide sequence of 15 to 30 consecutive nucleotides that shows 90% or more identity to the nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2; (II) A nucleic acid primer consisting of a base sequence of 15 to 30 consecutive bases in a base sequence complementary to a base sequence showing 90% or more identity to the base sequence shown in SEQ ID NO:1 or SEQ ID NO:2. [Item 2] The nucleic acid primer set according to Item 1, wherein the nucleic acid primers according to (I) and / or (II) above comprise a base sequence of 15 to 30 consecutive bases in the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto, or a base sequence in which one or several bases have been substituted, deleted, or added in said base sequence. [Item 3] The nucleic acid primer set according to Item 1 or 2, which is used for distinguishing and detecting Bordetella pertussis and Bordetella parapertussis as Bordetella genus bacteria. [Item 4] The nucleic acid primer set according to any one of Items 1 to 3, wherein the nucleic acid primer according to (I) above is a primer consisting of a nucleotide sequence shown in any one of SEQ ID NOs: 3 to 9. [Item 5] The nucleic acid primer set according to any one of Items 1 to 4, wherein the nucleic acid primer according to (II) above is a primer consisting of a nucleotide sequence shown in any one of SEQ ID NOs: 10 to 15. [Item 6] A method for distinguishing and detecting Bordetella bacteria that may be contained in a specimen, comprising the following steps (1) and (2): (1) performing a nucleic acid amplification reaction in a specimen using the nucleic acid primer set according to any one of items 1 to 5 to generate a nucleic acid amplification product; and (2) A step of detecting the amplification product obtained in the step (1). [Item 7] A method for distinguishing and detecting Bordetella bacteria according to Item 6, wherein the step (2) comprises the following steps (2-1) to (2-2): (2-1) hybridizing the nucleic acid amplification product obtained in the step (1) with a nucleic acid probe to form a complex; and (2-2) A step of detecting the complex obtained in the step (2-1). [Item 8] The detection method described in Item 6 or 7, which distinguishes between B. pertussis and B. parapertussis as Bordetella genus bacteria and detects them. [Item 9] The detection method according to any one of Items 6 to 8, wherein the nucleic acid probe used in the step (2-1) is a nucleic acid probe having the following characteristics (A) and (B): (A) a base sequence showing 85% or more identity to the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto, which contains a base sequence of at least 15 consecutive bases; and (B) At least one of the terminal bases is labeled with a fluorescent quenching dye that quenches fluorescence upon interaction with guanine. [Item 10] The detection method according to Item 9, wherein the base sequence of at least 15 bases described in (A) is a base sequence of at least 15 consecutive bases in the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto, or a base sequence in which one or several bases have been substituted, deleted, or added in such a base sequence. [Item 11] The detection method according to item 9 or 10, wherein the base sequence of at least 15 bases described in (A) consists of a base sequence shown in any one of SEQ ID NOs: 16 to 20. [Item 12] The detection method according to any one of Items 9 to 11, wherein the fluorescence quenching dye (B) is at least one fluorescence quenching dye selected from the group consisting of fluorescein and derivatives thereof, rhodamine and derivatives thereof, and BODIPY and derivatives thereof. [Item 13] The detection method according to any one of Items 9 to 12, wherein the fluorescence quenching dye (B) is at least one fluorescence quenching dye selected from the group consisting of 4,4-difluoro-5,7-dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-propionic acid (BODIPY-FL), carboxyrhodamine 6G, TAMRA, rhodamine 6G, tetrabromosulfone fluorescein (TBSF), and 2-oxo-6,8-difluoro-7-dihydroxy-2H-1-benzopyran-3-carboxylic acid (Pacific Blue). [Item 14] The detection method according to any one of Items 9 to 13, wherein in (B), at least one terminal base labeled with a fluorescence quenching dye is cytosine. [Item 15] The detection method according to any one of Items 7 to 14, wherein the step (2-2) includes at least one of the following steps (2-2a) to (2-2c): (2-2a) A step of hybridizing the nucleic acid probe to the obtainable amplification product and monitoring the progress of the nucleic acid amplification reaction in real time by measuring the fluorescence intensity of the reaction solution. (2-2b) After completion of the step (2-1), a step of hybridizing the nucleic acid probe to the amplification product that can be obtained and measuring the fluorescence intensity of the reaction solution to monitor the progress of the nucleic acid amplification reaction at an endpoint. (2-2c) A step of hybridizing the nucleic acid probe to the amplification product that can be obtained after completion of the step (2-1) and measuring the temperature dependence of the fluorescence intensity of the reaction solution. [Item 16] The detection method according to any one of Items 6 to 15, wherein the nucleic acid amplification reaction in the step (2) is PCR. [Item 17] The detection method according to any one of Items 6 to 16, wherein the nucleic acid amplification enzyme used in the nucleic acid amplification reaction in the step (2) is a DNA polymerase belonging to Family B. [Item 18] The detection method according to Item 17, wherein the DNA polymerase belonging to Family B is a DNA polymerase derived from KOD or a mutant thereof. [Item 19] The detection method according to any one of Items 6 to 18, wherein the specimen sample is a biological sample that has not been subjected to a nucleic acid purification step. [Item 20] A nucleic acid probe used to distinguish and detect Bordetella genus bacteria that may be contained in a specimen sample, the nucleic acid probe having the following characteristics (A) and (B): (A) a base sequence showing 85% or more identity to the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto, which contains a base sequence of at least 15 consecutive bases; and (B) At least one of the terminal bases is labeled with a fluorescent quenching dye that quenches fluorescence upon interaction with guanine. [Item 21] The nucleic acid probe described in Item 20, wherein the base sequence of at least 15 bases described in (A) is a base sequence of at least 15 consecutive bases in the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto, or a base sequence in which one or several bases have been substituted, deleted, or added in said base sequence. [Item 22] The nucleic acid probe according to Item 20 or 21, which is used to distinguish and detect B. pertussis and B. parapertussis as Bordetella genus bacteria. [Item 23] The nucleic acid probe according to any one of Items 20 to 22, wherein the base sequence of at least 15 bases described in (A) consists of a base sequence shown in any one of SEQ ID NOs: 16 to 20. [Item 24] The nucleic acid probe according to any one of Items 20 to 23, wherein the fluorescence quenching dye (B) is at least one fluorescence quenching dye selected from the group consisting of fluorescein and derivatives thereof, rhodamine and derivatives thereof, and BODIPY and derivatives thereof. [Item 25] The nucleic acid probe according to any one of Items 20 to 24, wherein the fluorescence quenching dye (B) is at least one fluorescence quenching dye selected from the group consisting of 4,4-difluoro-5,7-dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-propionic acid (BODIPY-FL), carboxyrhodamine 6G, TAMRA, rhodamine 6G, tetrabromosulfone fluorescein (TBSF), and 2-oxo-6,8-difluoro-7-dihydroxy-2H-1-benzopyran-3-carboxylic acid (Pacific Blue). [Item 26] The nucleic acid probe according to any one of Items 20 to 25, wherein in (B), at least one terminal base labeled with a fluorescence quenching dye is cytosine. [Item 27] ​​A reagent for distinguishing and detecting bacteria of the genus Bordetella, comprising the nucleic acid primer set according to any one of Items 1 to 5 and / or the nucleic acid probe according to any one of Items 20 to 26. [Item 28] The reagent described in Item 27, which is used to distinguish and detect B. pertussis and B. parapertussis as Bordetella genus bacteria. [Item 29] A kit for distinguishing and detecting Bordetella bacteria, comprising the nucleic acid primer set according to any one of Items 1 to 5, the nucleic acid probe according to any one of Items 20 to 26, and / or the reagent according to any one of Items 27 to 28. [Item 30] A kit according to Item 29 for distinguishing and detecting B. pertussis and B. parapertussis as Bordetella genus bacteria. Effect of the Invention

[0012] According to the present invention, Bordetella bacteria contained in a specimen can be easily and sensitively detected and differentiated from the specimen, and in particular Bordetella pertussis and Bordetella parapertussis can be detected and differentiated with high sensitivity. According to the method of the present invention, even when a sample in which nucleic acid has not been highly purified is used, it is difficult to be inhibited in amplification, and Bordetella bacteria can be detected and differentiated with sufficient sensitivity. By using the detection method, reagent, and kit using the oligonucleotide of the present invention, for example, Bordetella pertussis or Bordetella parapertussis can be easily and sensitively detected, which can greatly contribute to the field of clinical diagnosis. [Brief description of the drawings]

[0013] [Figure 1] FIG. 1 shows the results of Example 1. [Diagram 2] FIG. 1 shows the results of Example 2. [Diagram 3] FIG. 1 shows the results of Example 3. [Figure 4] FIG. 1 shows the results of Example 4. [Diagram 5] FIG. 1 shows the results of Example 6. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The present invention will be described in more detail below while showing embodiments of the present invention, but the present invention is not limited thereto. All non-patent documents and patent documents described in this specification are incorporated herein by reference. In addition, "~" in this specification means "more than or equal to, less than or equal to", for example, if "X~Y" is described in the specification, it means "more than or equal to X, less than or equal to Y". In addition, "and / or" in this specification means either one or both.

[0015] In addition, in this specification, a nucleic acid primer may be referred to as an oligonucleotide primer or simply as a primer, and a nucleic acid probe may be referred to as an oligonucleotide probe or simply as a probe, and these are collectively referred to as oligonucleotides.

[0016] (1. Methods for distinguishing and detecting Bordetella spp.) One embodiment of the present invention is a method for distinguishing and detecting Bordetella bacteria that may be contained in a specimen. More specifically, the method of the present invention includes at least the following steps (1) and (2): (1) performing a nucleic acid amplification reaction in a specimen using a nucleic acid primer set including a nucleic acid primer having a specific base sequence to generate a nucleic acid amplification product; and (2) detecting the amplification product obtained in the step (1); That is, one feature of the present invention is that a nucleic acid primer set including a nucleic acid primer with a specific base sequence is used in a nucleic acid amplification reaction in order to obtain highly sensitive determination results in the detection of Bordetella bacteria.

[0017] [Nucleic acid primer set] The nucleic acid primer set according to (1) above, which is used to distinguish and detect Bordetella bacteria in the present invention, includes a nucleic acid primer corresponding to the following (I) and a nucleic acid primer corresponding to the following (II): (I) a nucleic acid primer consisting of a nucleotide sequence of 15 to 30 consecutive nucleotides that shows 90% or more identity to the nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2; (II) A nucleic acid primer consisting of a base sequence of 15 to 30 consecutive bases in a base sequence complementary to a base sequence showing 90% or more identity to the base sequence shown in SEQ ID NO:1 or SEQ ID NO:2.

[0018] SEQ ID NO: 1 as defined in (I) and (II) above is a nucleotide sequence corresponding to a part of the genome sequence of Bordetella pertussis, a type of Bordetella bacteria. SEQ ID NO: 2 is a part of the genome sequence of Bordetella parapertussis, a type of Bordetella bacteria, and is a nucleotide sequence of a region showing homology to a part of the genome sequence of Bordetella pertussis shown in SEQ ID NO: 1. The nucleotide sequence shown in SEQ ID NO: 1 (Bordetella pertussis) and the nucleotide sequence shown in SEQ ID NO: 2 (Bordetella parapertussis) are genome regions showing high homology (about 99.6%), and the present invention is based on the discovery that Bordetella bacteria can be distinguished and detected with high sensitivity by performing a nucleic acid amplification reaction using this genome region as a target.

[0019] It is known that the genomic sequences of Bordetella pertussis and Bordetella parapertussis may differ slightly (for example, in one or several bases) depending on the strain. The present invention can also design the nucleic acid primer described in (I) or (II) above based on the genomic sequence of Bordetella pertussis or Bordetella parapertussis that differs in one or several bases in this way. Thus, the nucleic acid primer of the present invention as defined in (I) or (II) above may be a nucleic acid primer consisting of a 15 to 30 consecutive base sequence in a nucleotide sequence that shows 90% or more identity to the nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 or a nucleotide sequence complementary thereto. From the viewpoint of expecting a more specific nucleic acid amplification reaction, the base sequence of the nucleic acid primer is preferably a nucleic acid primer consisting of a base sequence of 15 to 30 consecutive bases that shows 93% or more, more preferably 95% or more, even more preferably 98% or more, and particularly preferably 100% identity to the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 or a base sequence complementary thereto.

[0020] In a specific embodiment, the nucleic acid primer described in (I) or (II) above may be, for example, a nucleic acid primer consisting of a 15 to 30 consecutive base sequence in the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 or a base sequence complementary thereto, or a base sequence in which one or several bases have been substituted, deleted, or added in the base sequence. Here, "one or several" may be, for example, 1 to 5, preferably 1 to 4, more preferably 1 to 3, and even more preferably 1 to 2. In this way, by using a nucleic acid primer having a base sequence highly homologous to the base sequence shown in SEQ ID NO: 1 or 2, a more specific nucleic acid amplification reaction may be possible.

[0021] The nucleic acid primer used in the present invention may be any that can amplify the genomic region of Bordetella bacteria corresponding to the nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, and may be a nucleic acid primer consisting of a nucleotide sequence of 15 to 30 consecutive bases in a region showing the same nucleotide sequence between SEQ ID NO: 1 and SEQ ID NO: 2, or may be a nucleic acid primer consisting of a nucleotide sequence of 15 to 30 consecutive bases in a region where some bases are different between SEQ ID NO: 1 and SEQ ID NO: 2. Furthermore, in the method of the present invention, a plurality of nucleic acid primers corresponding to the above (I) may be used, or a plurality of nucleic acid primers corresponding to the above (II) may be used. By using a plurality of primers corresponding to (I) and (II), a nucleic acid amplification reaction can also be performed by a multiplex method. From the viewpoint of enabling detection at a lower cost and with high sensitivity, a method of performing a nucleic acid amplification reaction using a nucleic acid primer set containing one type of nucleic acid primer corresponding to the above (I) and one type of nucleic acid primer corresponding to the above (II) is preferred.

[0022] In one preferred embodiment, the nucleic acid primer defined in (I) above is a nucleic acid primer consisting of a 15-30 consecutive base sequence in the 70th to 190th bases of the nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a complementary nucleotide sequence thereto. In this case, the nucleic acid primer defined in (II) above that is preferably used in combination is a nucleic acid primer consisting of a 15-30 consecutive base sequence in the 220th to 340th bases of the nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a complementary nucleotide sequence thereto. By generating a nucleic acid amplification product using such a combination of nucleic acid primers, it becomes possible to more effectively distinguish and detect Bordetella genus bacteria.

[0023] In another preferred embodiment, the nucleic acid primer defined in (I) above is a nucleic acid primer consisting of a 15-30 consecutive base sequence in the 300th to 390th bases of the 300th to 390th bases of the 30th base sequence ...

[0024] The length of the nucleic acid primers defined in (I) and (II) above is not particularly limited as long as it is 15 to 30 bases, but may be, for example, 16 to 25 bases, preferably 17 to 24 bases. By using a nucleic acid primer of such a length, it is possible to suppress non-specific amplification reactions while enabling a sufficient nucleic acid amplification reaction, and to generate a specific nucleic acid amplification product with high sensitivity.

[0025] In a specific preferred embodiment, a specific example of the nucleic acid primer described in (I) above can be a nucleic acid primer consisting of a base sequence shown in any of SEQ ID NOs: 3 to 9. In a further specific preferred embodiment, a specific example of the nucleic acid primer described in (II) above can be a nucleic acid primer consisting of a base sequence shown in any of SEQ ID NOs: 10 to 15. In particular, by using a nucleic acid primer set including a combination of the nucleic acid primers described in (I) and (II), it is possible to distinguish and detect Bordetella genus bacteria with even higher sensitivity.

[0026] [Nucleic acid amplification reaction] In one embodiment, the method of the present invention uses the above-mentioned nucleic acid primer set to carry out a nucleic acid amplification reaction to generate a nucleic acid amplification product. The nucleic acid amplification method is a technique for amplifying several copies of a target nucleic acid to a level at which it can be visualized, i.e., to hundreds of millions of copies or more, and is widely used not only in the field of life science research, but also in the fields of clinical diagnosis, food hygiene inspection, environmental inspection, etc. Examples of such nucleic acid amplification methods include PCR, LAMP, LCR, TMA, SDA, RT-PCR, RT-LAMP, NASBA, TRC, TMA, etc. These techniques have already been established in the technical field, and a method can be selected according to the purpose. The nucleic acid amplification method carried out in the present invention is preferably, but is not limited to, the PCR method (including the RT-PCR method).

[0027] [PCR reaction] PCR is a reaction catalyzed mainly by DNA polymerase, and the target nucleic acid is amplified by repeating three steps, namely (1) DNA denaturation by heat treatment (dissociation from double-stranded DNA to single-stranded DNA), (2) annealing of a primer to a template single-stranded DNA, and (3) extension of the primer using DNA polymerase, as one cycle. Examples of DNA polymerase include Taq, Tth, Bst, KOD, Pfu, Pwo, Tbr, Tfi, Tfl, Tma, Tne, Vent, DEEPVENT, and their variants. In view of being able to distinguish and detect Bordetella genus bacteria more simply and sensitively, it is preferable to use a DNA polymerase belonging to family B in the present invention.

[0028] The PCR reaction conditions are not particularly limited as long as the effects of the present invention are achieved, but for example, it is preferable to perform an initial heat deformation step at 80-100° C. for 0 seconds to 5 minutes, repeated heat deformation steps at 80-100° C. for 0.5-300 seconds, annealing at 35-80° C. for 1-300 seconds, and an extension reaction step at 35-85° C. for 1-300 seconds, and repeat this process 30-70 times. The temperature and time of the repeated cycles may be changed every one or several cycles.

[0029] [Family B DNA polymerase] The DNA polymerase used in the present invention is preferably, but is not limited to, a DNA polymerase belonging to family B. The DNA polymerase belonging to family B is not particularly limited, but is preferably a DNA polymerase derived from Archea, more preferably a DNA polymerase derived from bacteria of the genus Pyrococcus and Thermococcus. The present invention also includes a mutant of an archaea-derived DNA polymerase belonging to family B that does not lose its activity. The DNA polymerase mutant includes, but is not limited to, a mutant for the purpose of enhancing polymerase activity, deleting exonuclease activity, adjusting substrate specificity, etc. Examples of DNA polymerases derived from the genus Pyrococcus include, but are not limited to, DNA polymerases isolated from Pyrococcus furiosus, Pyrococcus sp. GB-D, Pyrococcus woesei, Pyrococcus abyssi, and Pyrococcus horikoshii, as well as mutants derived therefrom that have not lost their DNA polymerase activity. Examples of DNA polymerases derived from the genus Thermococcus include, but are not limited to, DNA polymerases isolated from Thermococcus kodakaraensis, Thermococcus gorgonarius, Thermococcus litoralis, Thermococcus sp. JDF-3, Thermococcus sp. 9 degrees North-7 (Thermococcus sp. 9°N-7), and Thermococcus siculi, and mutants thereof that have not lost their DNA polymerase activity. Preferably, DNA polymerases derived from Thermococcus kodakaraensis and mutants thereof (e.g., KOD-derived DNA polymerase lacking 3'→5' exonuclease activity) can be particularly preferably used in the present invention from the viewpoint of excellent extensibility and thermostability. PCR enzymes using these DNA polymerases are commercially available, and examples include Pfu (Staragene), KOD (Toyobo), Pfx (Life Technologies), Vent (New England Biolabs), Deep Vent (New England Biolabs), Tgo (Roche), and Pwo (Roche), any of which can be used in the present invention.

[0030] [DNA polymerase derived from KOD] In the present specification, KOD-derived DNA polymerase (also referred to as KOD DNA polymerase) refers to Thermococcus kodakaraensis-derived DNA polymerase and its variants (for example, KOD-derived DNA polymerase in which 3'→5' exonuclease activity has been deleted by substituting, deleting, and / or adding one or several amino acids in the naturally occurring amino acid sequence). In one preferred embodiment, the present invention performs a nucleic acid amplification reaction using such a KOD-derived DNA polymerase. KOD DNA polymerase is superior in accuracy, amplification efficiency, extensibility, and crude sample resistance compared to Taq DNA polymerase, which is a DNA polymerase belonging to family A. In the present invention, by using such a KOD DNA polymerase, it becomes possible to distinguish and detect Bordetella genus bacteria simply and with high sensitivity, as shown in the examples described later.

[0031] [Step of detecting the amplification product] In the method of the present invention, step (2) includes a step of detecting the amplification product obtained in step (1). The mode of this detection step is not particularly limited, and it can be carried out by any method known in the art.

[0032] In one embodiment, the step (2) includes the following steps (2-1) to (2-2): (2-1) hybridizing the nucleic acid amplification product obtained in the step (1) with a nucleic acid probe to form a complex; and (2-2) A step of detecting the complex obtained in the step (2-1). In a preferred embodiment, one of the features of the present invention is that a nucleic acid probe capable of specifically reacting with the nucleic acid amplification product obtained in the step (1) to form a complex is used in order to obtain highly sensitive determination results in the detection of Bordetella bacteria.

[0033] [Nucleic acid probe] In one embodiment, the present invention uses a nucleic acid probe capable of specifically reacting with a nucleic acid amplification product amplified with a nucleic acid primer set including a nucleic acid primer having the specific base sequence to form a complex.

[0034] The base sequence of the nucleic acid probe is preferably relatively highly homologous to the base sequence of SEQ ID NO: 1 and / or SEQ ID NO: 2 that can be amplified by the nucleic acid primers (I) and (II). For example, the nucleic acid probe used in the present invention may be a nucleic acid probe consisting of a base sequence showing 85% or more identity with the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto, with at least 15 consecutive bases. Preferably, the nucleic acid probe may be a nucleic acid probe consisting of a base sequence of at least 15 consecutive bases in a base sequence showing 90% or more identity, more preferably 93% or more identity, even more preferably 95% or more identity, even more preferably 98% or more identity with the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto. Particularly preferably, the nucleic acid probe is a nucleic acid probe consisting of a base sequence 100% identical to the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence of at least 15 consecutive bases in a base sequence complementary thereto.

[0035] In a specific embodiment, the nucleic acid probe may be, for example, a nucleic acid probe consisting of a base sequence in which one or several bases have been substituted, deleted, or added in the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2. Here, one or several may be, for example, 1 to 5, preferably 1 to 4, more preferably 1 to 3, and even more preferably 1 to 2. In this way, by using a nucleic acid probe having a base sequence highly homologous to the base sequence shown in SEQ ID NO: 1 or 2, it becomes possible to distinguish and detect Bordetella bacteria with high sensitivity.

[0036] The nucleic acid probe of the present invention is not particularly limited as long as it has the base sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or a sequence highly homologous to a base sequence complementary thereto. However, when the nucleic acid probe is labeled with a fluorescent quenching dye that is quenched by interaction with guanine as described below, it is preferable that at least one terminal base labeled with the dye is cytosine.

[0037] In one preferred embodiment, the nucleic acid probe of the present invention is a nucleic acid probe consisting of a base sequence of at least 15 consecutive bases in the base sequence shown at positions 190 to 220 of the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto. By reacting such a nucleic acid probe with a nucleic acid amplification product, it becomes possible to more effectively distinguish and detect Bordetella bacteria.

[0038] In another preferred embodiment, the nucleic acid probe of the present invention is a nucleic acid probe consisting of a base sequence of at least 15 consecutive bases in the base sequence shown at positions 400 to 440 of the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto. By reacting such a nucleic acid probe with a nucleic acid amplification product, it becomes possible to more effectively distinguish and detect Bordetella bacteria.

[0039] The length of the nucleic acid probes defined in (I) and (II) above is not particularly limited as long as it is 15 bases or more, but may be, for example, 15 to 25 bases, preferably 16 to 19 bases. By using a nucleic acid probe of such a length, it is possible to more sensitively distinguish and detect Bordetella bacteria.

[0040] In a specific preferred embodiment, a specific example of the nucleic acid probe used in the present invention is a nucleic acid probe having a base sequence shown in any one of SEQ ID NOs: 16 to 20. By using a nucleic acid probe having such a specific base sequence, it becomes possible to distinguish and detect Bordetella bacteria with even higher sensitivity.

[0041] The nucleic acid probe may or may not be labeled. When labeled, the number of nucleic acids to be labeled is not particularly limited. Preferably, the nucleic acid at the end of the nucleic acid probe is labeled, and more preferably, only one of the nucleic acids at the end is labeled. There is no particular limit to the labeling substance, but it is more preferably a fluorescent substance.

[0042] The fluorescent label may be either a fluorescent substance that emits fluorescence or a fluorescent substance that quenches fluorescence by hybridizing with a target nucleic acid amplification product to form a complex, but is preferably a fluorescent substance that quenches fluorescence when hybridized with a target nucleic acid amplification product, and is particularly preferably a fluorescence quenching dye that is quenched by interaction with guanine when hybridized with a target nucleic acid amplification product (for example, a fluorescence quenching dye that is quenched by interaction with guanine). Specific examples of the fluorescent quenching dye include, but are not limited to, at least one fluorescent quenching dye selected from the group consisting of fluorescein and its derivatives (e.g., fluorescein isothiocyanate (FITC)), rhodamine and its derivatives (e.g., 5-carboxyrhodamine 6G (GR6G), tetramethylrhodamine (TAMRA), carboxyrhodamine, x-rhodamine, sulforhodamine 101 acid chloride), and BODIPY and its derivatives (e.g., BODIPY-FL, BODIPY-FL / C3, BODIPY-FL / C6, BODIPY-5-FAM, BODIPY-TMR, BODIPY-TR, BODIPY-R6G, BODIPY-564, BODIPY-581, BODIPY-591, BODIPY-630, BODIPY-650, BODIPY-665).

[0043] More specifically, examples of the fluorescence quenching dye that is quenched by interaction with guanine include at least one fluorescence quenching dye selected from the group consisting of 4,4-difluoro-5,7-dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-propionic acid (BODIPY-FL), carboxyrhodamine 6G, TAMRA, rhodamine 6G, tetrabromosulfonefluorescein (TBSF), and 2-oxo-6,8-difluoro-7-dihydroxy-2H-1-benzopyran-3-carboxylic acid (Pacific Blue), and these fluorescence quenching dyes can be suitably used in the present invention.

[0044] In a particularly preferred embodiment, a nucleic acid probe in which at least one terminal base labeled with a fluorescence quenching dye (that is, when both ends are labeled, at least one terminal base) is cytosine is more preferred. When such oligonucleotide probes hybridize to amplification products, they can quench the light by forming base pairs with the guanine bases in the amplification products and interacting with them, making it very easy to measure changes in the fluorescence intensity of the reaction solution.

[0045] In addition, when the probe is hybridized, even if the cytosine base of the probe and the guanine base in the amplified product do not form a base pair, the fluorescence can be quenched as long as the distance between these bases is close. For example, details are described in Japanese Patent No. 5354216, and the present invention can also refer to this technology. That is, when the probe is hybridized, the fluorescence can be quenched if the guanine base in the amplified product is present within a range of, for example, 1 to 3 bases relative to the cytosine base of the probe (a base that forms a base pair with the cytosine base is considered to be 1).

[0046] In a further specific embodiment, even if at least one terminal base labeled with a fluorescence quenching dye (i.e., when both ends are labeled, at least one terminal base) is not cytosine in a nucleic acid probe, the change in fluorescence intensity of the reaction solution can be measured. For example, details are described in Japanese Patent No. 5354216, and the present invention can also refer to this technology. For example, when the probe hybridizes, quenching can be achieved if a guanine base in the amplification product is present within a range of, for example, 1 to 3 bases relative to at least one terminal base labeled with a fluorescence quenching dye (a base that forms a base pair with the terminal base is counted as 1).

[0047] [Step of detecting the complex] In the step of detecting the amplification product of the present invention, the embodiment of the step (2-2) of detecting a complex formed by hybridization of the nucleic acid amplification product with the nucleic acid probe is not particularly limited, and can be carried out by any method known in the art.

[0048] In one embodiment, the step (2-2) may include at least one of the following steps (2-2a) to (2-2c): (2-2a) A step of hybridizing the nucleic acid probe to the obtainable amplification product and monitoring the progress of the nucleic acid amplification reaction in real time by measuring the fluorescence intensity of the reaction solution. (2-2b) After completion of the step (2-1), a step of hybridizing the nucleic acid probe to the amplification product that can be obtained and measuring the fluorescence intensity of the reaction solution to monitor the progress of the nucleic acid amplification reaction at an endpoint. (2-2c) A step of hybridizing the nucleic acid probe to the amplification product that can be obtained after completion of the step (2-1) and measuring the temperature dependence of the fluorescence intensity of the reaction solution. According to the above steps (2-2a) to (2-2c), it may be possible to simply and sensitively detect the formation of a complex between a nucleic acid amplification product and a nucleic acid probe.

[0049] [(2-2a) Real-time monitoring of the progress of nucleic acid amplification reactions] By monitoring the progress of the nucleic acid amplification reaction in real time, the target nucleic acid contained in the sample can be rapidly detected, and further, the amount of the target nucleic acid contained in the sample can be quantified based on the amplification rate. For example, the progress of the nucleic acid amplification reaction is monitored in real time by measuring the fluorescence intensity of a reaction solution containing an oligonucleotide probe labeled with a fluorescent quenching dye. The fluorescence intensity of the reaction solution is measured at any time during the nucleic acid amplification reaction. If the sample contains DNA from Bordetella pertussis or Bordetella parapertussis, the oligonucleotide probe hybridizes to the amplified nucleic acid, increasing (or decreasing) the fluorescence intensity depending on the amount of amplified nucleic acid. The progress of the nucleic acid amplification reaction can be monitored in real time by plotting the obtained fluorescence intensity against time (cycle number in the case of a PCR reaction).

[0050] [(2-2b) Monitoring the progress of nucleic acid amplification reactions at endpoints] By monitoring the progress of the nucleic acid amplification reaction at the end point, the target nucleic acid contained in the sample can be detected quickly, and the amount of the target nucleic acid can be quantified by comparing the fluorescence intensity at the end point. For example, the progress of the nucleic acid amplification reaction is monitored at an end point by measuring the fluorescence intensity of a reaction solution containing an oligonucleotide probe labeled with a fluorescent quenching dye (for example, Example 3). After the nucleic acid amplification reaction is completed, the fluorescence intensity of the reaction solution is measured. The presence or absence of amplification of the target nucleic acid can be confirmed by comparing the fluorescence intensity of the reaction solution after the reaction with the fluorescence intensity of the reaction solution before the reaction. Alternatively, the presence or absence of the target nucleic acid contained in the sample can also be confirmed by comparing the reaction intensity of the reaction solution after the reaction with the reaction intensity of a control reaction solution. A control reaction solution is a reaction solution to which a sample known to be negative or positive is added instead of the sample to be measured. It is generally preferable to monitor the progress of the nucleic acid amplification reaction in real time, but for the purpose of making the detection step more convenient, it is preferable to monitor it at an end point.

[0051] [(2-2c) Measuring the temperature dependence of fluorescence intensity] Measuring the temperature dependency of fluorescence intensity specifically means measuring the fluorescence intensity at each temperature while changing the temperature of the reaction solution from low to high (for example, Example 4). The melting temperature (Tm value) specific to the oligonucleotide probe used can be obtained by first differentiating the obtained fluorescence intensity with respect to temperature. In addition, the fluorescence intensity may be converted into a fluorescence quenching rate or the like according to the purpose. The detection and analysis of target nucleic acids using the Tm value is called melting curve analysis. In general, the Tm value refers to the temperature at which the proportion of an oligonucleotide that forms a double strand with its complementary strand is equal to the proportion that does not form a double strand and is single-stranded. Since the Tm value is a value specific to a base sequence, melting curve analysis can be used as a method for analyzing base sequence polymorphisms of target nucleic acids. Base sequence polymorphisms referred to here include single nucleotide polymorphisms, base substitutions, base deletions, base insertions, etc.

[0052] For example, melting curve analysis is also applied to SNP analysis. When there is a mutation in the base sequence of the target nucleic acid relative to the oligonucleotide probe, the bases are mismatched when the probe hybridizes, and the Tm value is generally low. Therefore, single nucleotide polymorphism analysis (SNP analysis) can be performed by comparing the magnitude of the Tm value.

[0053] [Specimen] The specimen sample that can be used in the present invention is not particularly limited as long as it may contain Bordetella bacteria. For example, oral scrapings, pharyngeal swabs, nasal swabs, nasal aspirates, sputum, bronchial lavage fluid, alveolar lavage fluid, etc. collected from subjects suspected of infection with Bordetella pertussis or B. parapertussis are included, but are not limited to these. When a biological sample is used as the specimen sample to be measured, pretreatment such as dilution, suspension, centrifugation, or nucleic acid extraction may be performed depending on each biological sample, although this is not particularly limited.

[0054] The method of collecting and preparing the specimen is not particularly limited, and known methods can be used depending on the type and purpose of the sample. In a specific preferred embodiment, the specimen used in the present invention can be a sample obtained by treating a specimen collected from a living body with alkali (e.g., pH 8.0 to 14.0, preferably pH 10.0 to 13.0).

[0055] The method for extracting nucleic acid is not particularly limited, and any known method can be used depending on the type and purpose of the sample. For example, a kit sold by each manufacturer may be used for nucleic acid extraction.

[0056] In a specific preferred embodiment, the method of the present invention does not require a nucleic acid purification step that is usually considered essential in conventional nucleic acid amplification reactions. As shown in the results of the test examples described below, it has been confirmed that the method of the present invention can distinguish and detect Bordetella bacteria with high sensitivity even in specimen samples containing contaminants such as biological components other than the target nucleic acid (which may be inhibitors of the nucleic acid amplification reaction). In addition to the need for dedicated reagents, nucleic acid purification has the problem of complicated work, which is time-consuming and laborious. However, according to the gene amplification reaction of the present invention, there is no need to prepare a dedicated device for such nucleic acid purification, and it is possible to eliminate complicated operations. Furthermore, since the time required for centrifugation can be shortened, the time from collection of a biological sample from a subject to obtaining a genetic test result can be shortened, and for example, the time from collection of a sample to obtaining a genetic test result can be within one day, preferably within half a day, more preferably within six hours, even more preferably within three hours, and especially preferably within two hours (for example, within one and a half hours). In this way, the method of the present invention, which can perform detection using biological samples that have not undergone a nucleic acid purification process, is preferable because it can eliminate the need for the labor of nucleic acid purification and enables Bordetella genus bacteria to be detected simply and quickly.

[0057] [Bacteria of the genus Bordetella] Bordetella genus bacteria are known as gram-negative coccobacilli that are known to be causative bacteria of various respiratory diseases. Bordetella genus bacteria are known to be causative bacteria of various infectious diseases, such as B. pertussis, which causes Bordetella pertussis, B. parapertussis, which causes Bordetella pertussis, and B. bronchiseptica, which causes bronchitis. According to the method of the present invention, any of these Bordetella genus bacteria can be detected with high sensitivity. Preferably, the method of the present invention can accurately detect and distinguish B. pertussis from B. parapertussis.

[0058] [Reagents for the differential detection of Bordetella species] Another embodiment of the present invention is a reagent for distinguishing and detecting Bordetella bacteria that may be contained in a sample. The reagent contains at least components necessary for nucleic acid amplification in addition to the nucleic acid primer set and / or nucleic acid probe of the present invention described above. The necessary components differ depending on the nucleic acid amplification reaction to be performed, and a known method can be used for each. For example, when detecting Bordetella bacteria that may be contained in a sample using a PCR reaction, it is preferable to contain at least DNA polymerase, deoxyribonucleoside triphosphates (dNTPs), and inorganic salts such as magnesium salts. The concentration of each component can be appropriately adjusted depending on the intended experiment, and for example, the nucleic acid primer is preferably 0.01 to 10 μM. The nucleic acid probe is preferably 0.01 to 1 μM, more preferably 0.02 to 0.5 μM. The DNA polymerase is preferably 0.01 to 1 U / uL, more preferably 0.02 to 0.5 U / uL. The concentration of deoxyribonucleoside triphosphates (dNTPs) is preferably 0.02 to 1 mM, and more preferably 0.1 to 0.5 mM. The concentration of inorganic salts such as magnesium salts is preferably 0.1 to 10 mM, and more preferably 1 to 5 mM.

[0059] Furthermore, additives known in the art may be added for the purpose of suppressing non-specific amplification or promoting the reaction. Known anti-DNA polymerase antibodies, phosphoric acid, etc. may be used as additives for suppressing non-specific amplification. Additives for promoting the reaction include bovine serum albumin (BSA), protease inhibitors, single-strand binding protein (SSB), T4 gene 32 protein, tRNA, sulfur- or acetic acid-containing compounds, dimethyl sulfoxide (DMSO), glycerol, ethylene glycol, propylene glycol, trimethylene glycol, formamide, acetamide, betaine, ectoine, trehalose, dextran, polyvinylpyrrolidone (PVP), gelatin, tetramethylammonium chloride (TMAC), tetramethylammonium hydroxide (TMAH), tetramethylammonium acetate (TMAA), polyethylene glycol, Triton, Tween 20, and Nonidet P40. In the present invention, one or more of these additives may be used in combination, but is not limited to these.

[0060] [Kit for distinguishing and detecting Bordetella spp.] Another embodiment of the present invention is a kit for distinguishing and detecting Bordetella bacteria that may be contained in a sample. The kit of the present invention is not particularly limited as long as it contains the above-described nucleic acid primer set of the present invention, the nucleic acid probe, and / or a reagent containing them, and is configured to distinguish and detect Bordetella bacteria. For example, the kit of the present invention can optionally contain a genetic testing reagent capable of detecting or quantifying the presence of a target substance and / or an instruction manual explaining a method of use, etc. For example, the nucleic acid primer set and the nucleic acid probe can be enclosed in the same container or in separate containers, and can be packaged in, for example, a single package and provided in a form including information on the method of use of the kit. EXAMPLES

[0061] The present invention will be described in detail below with reference to examples, but the present invention is not limited to the following examples.

[0062] Example 1: Detection of Bordetella pertussis (1) Sample preparation DNA samples extracted from B. pertussis or B. parapertussis were diluted with sterile water to 100 copies / μL each, and used as samples. (2) Nucleic acid amplification and melting curve analysis The above samples were added to the following reagents, and Bordetella pertussis or Bordetella parapertussis was detected under the following conditions. GENECUBE (registered trademark) manufactured by Toyobo was used for nucleic acid amplification and melting curve analysis.

[0063] reagent A solution containing the following reagents was prepared: KOD Mix (GeneCube(R) Test Basic, Toyobo) 3μL PPD Mix (GeneCube(R) Test Basic, Toyobo) 1μL IC Mix (GeneCube(R) Test Basic, Toyobo) 1μL 10 μM primer represented by SEQ ID NO:5 0.25 μL 10 μM primer shown in SEQ ID NO: 11 1.5 μL 10 μM Probe shown in SEQ ID NO: 16 0.25 μL 3μL of sample

[0064] Nucleic acid amplification and melting curve analysis 94℃・2 minutes (One cycle) 97℃・1 second 58℃・3 seconds 63℃・5 seconds (more than 60 cycles) 94℃・30 seconds 39℃・30 seconds 39℃~75℃ (Temperature rises at 0.09℃ / sec)

[0065] (3) Results Figure 1 shows the results of melting curve analysis of changes in fluorescence intensity with increasing temperature after nucleic acid amplification under the above conditions, with the horizontal axis representing temperature and the vertical axis representing the differential value of the fluorescence signal. In the graph, BP genome represents the analysis results of B. pertussis genomic DNA, BPP genome represents the analysis results of B. parapertussis genomic DNA samples, and NC represents the analysis results of sterilized water. As is clear from Figure 1, it can be seen that B. pertussis and B. parapertussis can be detected separately by the present invention.

[0066] Example 2: Detection of Bordetella pertussis (1) Sample preparation A DNA sample (BP genome) extracted from Bordetella pertussis was suspended in saline and mixed with nasal or pharyngeal swabs to prepare a pseudo-biological sample at 10 copies / μL. This pseudo-biological sample was used as is without further nucleic acid extraction or purification, and therefore corresponds to a sample containing biological contaminants. (2) Nucleic acid amplification and melting curve analysis The above samples were added to the following reagents, and Bordetella pertussis was detected under the following conditions. GENECUBE (registered trademark) manufactured by Toyobo was used for nucleic acid amplification and melting curve analysis.

[0067] reagent A solution containing the following reagents was prepared: KOD Mix (GeneCube(R) Test Basic, Toyobo) 3μL PPD Mix (GeneCube(R) Test Basic, Toyobo) 1μL IC Mix (GeneCube(R) Test Basic, Toyobo) 1μL 10 μM primer represented by SEQ ID NO: 12 0.25 μL 10 μM primer represented by SEQ ID NO:3 1.5 μL 10 μM Probe shown in SEQ ID NO: 17 0.25 μL 3μL of sample

[0068] Nucleic acid amplification and melting curve analysis 94℃・2 minutes (One cycle) 97℃・1 second 60℃・3 seconds 63℃・6 seconds (more than 60 cycles) 94℃・30 seconds 39℃・30 seconds 39℃~75℃ (Temperature rises at 0.09℃ / sec)

[0069] (3) Results Figure 2 shows the results of nucleic acid amplification and detection performed under the above conditions. The results are shown for postnasal swabs and pharyngeal swabs to which Bordetella pertussis genomic DNA was added. As shown in Figure 2, Bordetella pertussis was detected in the postnasal swabs and pharyngeal swabs. This result revealed that, completely unexpectedly, Bordetella pertussis could be detected without being inhibited by amplification contained in the specimen.

[0070] Example 3: Detection of Bordetella pertussis (1) Sample preparation A DNA sample (BP genome) extracted from Bordetella pertussis was suspended in saline and mixed with nasal or pharyngeal swabs to prepare a pseudo-biological sample at 10 copies / μL. This pseudo-biological sample was used as is without further nucleic acid extraction or purification, and therefore corresponds to a sample containing biological contaminants. (2) Nucleic acid amplification and melting curve analysis The above samples were added to the following reagents, and Bordetella pertussis was detected under the following conditions. GENECUBE (registered trademark) manufactured by Toyobo was used for nucleic acid amplification and melting curve analysis.

[0071] reagent A solution containing the following reagents was prepared: KOD Mix (GeneCube(R) Test Basic, Toyobo) 3μL PPD Mix (GeneCube(R) Test Basic, Toyobo) 1μL IC Mix (GeneCube(R) Test Basic, Toyobo) 1μL 10 μM primer represented by SEQ ID NO: 8 0.25 μL 10 μM primer represented by SEQ ID NO: 15 1.5 μL 10 μM Probe shown in SEQ ID NO: 19 0.25 μL 3μL of sample

[0072] Nucleic acid amplification and melting curve analysis 94℃・2 minutes (One cycle) 97℃・1 second 60℃・3 seconds 63℃・6 seconds (more than 60 cycles) 94℃・30 seconds 39℃・30 seconds 39℃~75℃ (Temperature rises at 0.09℃ / sec)

[0073] (3) Results Fig. 3 shows the results of nucleic acid amplification detection performed under the above conditions. The results show the measurement results of postnasal swabs or pharyngeal swabs to which Bordetella pertussis genomic DNA was added. As shown in Fig. 3, Bordetella pertussis was also detected in postnasal swabs and pharyngeal swabs. These samples are known to contain nucleic acid amplification inhibitors such as viscous substances (e.g., mucin) derived from living organisms. The results of this example demonstrated that Bordetella pertussis can be detected without being affected by the amplification inhibition contained in such samples.

[0074] Example 4: Detection of B. parapertussis (1) Sample preparation The throat swab was suspended in eSwab medium (manufactured by Copan), and a DNA sample (BPP genome) extracted from B. parapertussis was mixed with the throat swab suspended in eSwab medium to prepare a concentration of 2 copies / μL, which was used as a pseudo-biological sample. This pseudo-biological sample was used as is without further nucleic acid extraction and purification, and therefore corresponds to a sample containing contaminating substances derived from living organisms. In addition, a DNA sample (BPP genome) extracted from B. parapertussis was prepared with sterile water to a concentration of 2 copies / μL, which was used as a positive sample. (2) Nucleic acid amplification and melting curve analysis The above sample was added to the following Example Reagent and Comparative Example Reagent, and B. parapertussis was detected under the following conditions: GENECUBE (registered trademark) manufactured by Toyobo was used for nucleic acid amplification and melting curve analysis.

[0075] reagent A solution containing the following reagents was prepared as an example: KOD Mix (GeneCube(R) Test Basic, Toyobo) 3μL PPD Mix (GeneCube(R) Test Basic, Toyobo) 1μL IC Mix (GeneCube(R) Test Basic, Toyobo) 1μL 10 μM primer represented by SEQ ID NO:6 0.25 μL 10 μM primer represented by SEQ ID NO: 10 1.5 μL 10 μM Probe shown in SEQ ID NO: 18 0.25 μL 3μL of sample

[0076] In addition, as a comparative example, a substantially identical reagent was prepared except that the following nucleic acid primers and nucleic acid probes (SEQ ID NOs: 21 to 23: nucleic acid primers and nucleic acid probes described in Patent Document 3) different from those of the present invention were used, and used in a comparison experiment. 10 μM primer represented by SEQ ID NO: 21 0.25 μL 10 μM Probe shown in SEQ ID NO: 22 0.25 μL 10 μM primer represented by SEQ ID NO: 23 1.5 μL

[0077] Nucleic acid amplification and melting curve analysis 94℃・2 minutes (One cycle) 97℃・1 second 58℃・3 seconds 63℃・6 seconds (more than 60 cycles) 94℃・30 seconds 39℃・30 seconds 39℃~75℃ (Temperature rises at 0.09℃ / sec)

[0078] (3) Results FIG. 4 shows the detection results of nucleic acid amplification detection performed under the above conditions. In both the reagent of this embodiment and the reagent of the comparative example, Bordetella parapertussis was detected in the positive samples. On the other hand, in the pseudo-biological sample, the reagent of the comparative example was unable to detect Bordetella due to amplification inhibition caused by substances contained in the specimen, whereas it was revealed that the present reagent was not inhibited and could detect Bordetella with high sensitivity. From the results of this embodiment, it can be seen that by using the nucleic acid primer and nucleic acid probe of the present invention, the influence of impurities that may inhibit the amplification reaction can be suppressed and Bordetella bacteria can be detected with high sensitivity even in biological samples that have not been subjected to a nucleic acid purification process.

[0079] Example 5: Detection of Bordetella pertussis and Bordetella parapertussis (1) Sample preparation DNA samples extracted from Bordetella pertussis and Bordetella parapertussis were adjusted to 0.5 (copies / μL), 0.25 (copies / μL), 0.15 (copies / μL), and 0.075 (copies / μL), respectively, with sodium hydroxide solution to prepare samples (pH 12.4 after adjustment). (2) Nucleic acid amplification and melting curve analysis The above samples were added to the following reagents, and Bordetella pertussis and Bordetella parapertussis were measured under the following conditions (n=4). GENECUBE (registered trademark) manufactured by Toyobo was used for nucleic acid amplification and melting curve analysis.

[0080] reagent A solution containing the following reagents was prepared: KOD Mix (GeneCube(R) Test Basic, Toyobo) 4μL PPD Mix (GeneCube(R) Test Basic, Toyobo) 1.9μL IC Mix (GeneCube(R) Test Basic, Toyobo) 1.3μL 10 μM primer represented by SEQ ID NO:5 0.25 μL 10 μM primer shown in SEQ ID NO: 11 1.5 μL 10 μM Probe shown in SEQ ID NO: 18 0.25 μL Sample 4μL

[0081] Nucleic acid amplification and melting curve analysis 94℃・2 minutes (One cycle) 97℃・1 second 58℃・3 seconds 63℃・6 seconds (more than 60 cycles) 94℃・30 seconds 39℃・30 seconds 39℃~75℃ (Temperature rises at 0.09℃ / sec)

[0082] (3) Results Table 1 below summarizes the results of nucleic acid amplification detection under the above conditions, and detection of low concentrations of Bordetella pertussis and Bordetella parapertussis. The numbers detected are shown for n=4 measurements. Table 1 shows that Bordetella pertussis can be detected down to 0.25 copies / μL, and Bordetella parapertussis can be detected down to 0.15 copies / μL, demonstrating that high sensitivity is possible even in the case of low copy numbers.

[0083] [Table 1]

[0084] Example 6: Detection of Bordetella pertussis and Bordetella parapertussis (1) Sample preparation The following tests were performed using samples that were confirmed to be positive for Bordetella pertussis or Bordetella parapertussis by suspending the postnasal swab and pharyngeal swab in water and detecting Bordetella spp. using another method (real-time PCR). These samples were used as they were without further nucleic acid extraction or purification. (2) Nucleic acid amplification and melting curve analysis The above samples were added to the following reagents, and Bordetella pertussis and Bordetella parapertussis were measured under the following conditions. GENECUBE (registered trademark) manufactured by Toyobo was used for nucleic acid amplification and melting curve analysis.

[0085] reagent A solution containing the following reagents was prepared: KOD Mix (GeneCube(R) Test Basic, Toyobo) 3μL PPD Mix (GeneCube(R) Test Basic, Toyobo) 1μL IC Mix (GeneCube(R) Test Basic, Toyobo) 1μL 10 μM primer represented by SEQ ID NO: 4 0.25 μL 10 μM primer represented by SEQ ID NO: 10 1.5 μL 10 μM Probe shown in SEQ ID NO: 18 0.25 μL 3μL of sample

[0086] Nucleic acid amplification and melting curve analysis 94℃・2 minutes (One cycle) 97℃・1 second 58℃・3 seconds 63℃・6 seconds (more than 60 cycles) 94℃・30 seconds 39℃・30 seconds 39℃~75℃ (Temperature rises at 0.09℃ / sec)

[0087] (3) Results Figure 5 shows the results of nucleic acid amplification and detection performed under the above conditions. It can be seen that this reagent was able to detect and distinguish between Bordetella pertussis and Bordetella parapertussis with sufficient sensitivity, even in actual specimens (positive specimens) that contained biological contaminants. [Industrial Applicability]

[0088] By using the nucleic acid primer set and / or nucleic acid probe of the present invention, it has become possible to easily and sensitively detect and distinguish Bordetella bacteria that may be contained in a sample. Therefore, for example, the present invention makes it possible to easily and accurately detect and distinguish B. pertussis and B. parapertussis, which have been difficult to distinguish in the past, and can greatly contribute to clinical diagnosis, etc.

Claims

1. A nucleic acid primer set for distinguishing between Bordetella pertussis and Bordetella parapertussis, which is a combination of a primer consisting of a nucleotide sequence shown in any one of SEQ ID NOs: 3 to 6 and a primer consisting of a nucleotide sequence shown in any one of SEQ ID NOs: 10 to 12, or a combination of a primer consisting of a nucleotide sequence shown in SEQ ID NO: 8 and a primer consisting of a nucleotide sequence shown in SEQ ID NO:

15.

2. A method for distinguishing and detecting B. pertussis and B. parapertussis that may be contained in a specimen sample, comprising the following steps (1) and (2): (1) carrying out a nucleic acid amplification reaction in a specimen sample using the nucleic acid primer set according to claim 1 to generate a nucleic acid amplification product; and (2) A step of detecting the amplification product obtained in the step (1).

3. The method according to claim 2, wherein the step (2) comprises the following steps (2-1) to (2-2): (2-1) hybridizing the nucleic acid amplification product obtained in the step (1) with a nucleic acid probe to form a complex; and (2-2) A step of detecting the complex obtained in the step (2-1).

4. The method according to claim 3, wherein the nucleic acid probe used in the step (2-1) is a nucleic acid probe having the following characteristics (A) and (B): (A) a base sequence of at least 15 consecutive bases in the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto; and (B) At least one of the terminal bases is labeled with a fluorescent quenching dye that quenches fluorescence upon interaction with guanine.

5. The method according to claim 4, wherein the base sequence of at least 15 bases described in (A) is a base sequence of at least 15 consecutive bases in the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto, or a base sequence in which one or several bases have been substituted, deleted, or added in said base sequence.

6. The method according to claim 4 or 5, wherein the base sequence of at least 15 bases described in (A) consists of a base sequence shown in any one of SEQ ID NOs: 16 to 20.

7. The method according to any one of claims 4 to 6, wherein the fluorescence quenching dye (B) is at least one fluorescence quenching dye selected from the group consisting of fluorescein and derivatives thereof, rhodamine and derivatives thereof, and BODIPY and derivatives thereof.

8. The method according to any one of claims 4 to 7, wherein the fluorescence quenching dye (B) is at least one fluorescence quenching dye selected from the group consisting of 4,4-difluoro-5,7-dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-propionic acid (BODIPY-FL), carboxyrhodamine 6G, TAMRA, rhodamine 6G, tetrabromosulfonefluorescein (TBSF), and 2-oxo-6,8-difluoro-7-dihydroxy-2H-1-benzopyran-3-carboxylic acid (Pacific Blue).

9. The method according to any one of claims 4 to 8, wherein in (B), at least one terminal base labeled with a fluorescent quenching dye is cytosine.

10. The method according to any one of claims 3 to 9, wherein the step (2-2) includes at least one of the following steps (2-2a) to (2-2c): (2-2a) A step of monitoring the progress of the nucleic acid amplification reaction in real time by measuring the fluorescence intensity of a reaction solution containing or not containing a complex formed by hybridizing the nucleic acid probe to the nucleic acid amplification product. (2-2b) monitoring the progress of the nucleic acid amplification reaction at an endpoint by measuring the fluorescence intensity of a reaction solution that either contains or does not contain a complex formed by hybridizing the nucleic acid probe to the nucleic acid amplification product. (2-2c) A step of measuring the temperature dependence of the fluorescence intensity of a reaction solution containing or not containing a complex formed by hybridizing the nucleic acid amplification product with the nucleic acid probe.

11. The method according to any one of claims 2 to 10, wherein the nucleic acid amplification reaction in the step (1) is PCR.

12. The method according to any one of claims 2 to 11, wherein the nucleic acid amplification enzyme used in the nucleic acid amplification reaction in the step (1) is a DNA polymerase belonging to family B.

13. The method according to claim 12, wherein the DNA polymerase belonging to family B is a KOD-derived DNA polymerase or a mutant thereof.

14. The method according to any one of claims 2 to 13, wherein the specimen sample is a biological sample that has not been subjected to a step of purifying nucleic acid.

15. A reagent for distinguishing and detecting B. pertussis and B. parapertussis, comprising the nucleic acid primer set according to claim 1 and a nucleic acid probe having the following characteristics (A) and (B): (A) a base sequence of at least 15 consecutive bases in the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto; and (B) At least one of the terminal bases is labeled with a fluorescent quenching dye that quenches fluorescence upon interaction with guanine.

16. A kit for distinguishing and detecting B. pertussis and B. parapertussis, comprising the nucleic acid primer set according to claim 1, and a nucleic acid probe having the following characteristics (A) and (B) and / or the reagent according to claim 15: (A) a base sequence of at least 15 consecutive bases in the base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2, or a base sequence complementary thereto; and (B) At least one of the terminal bases is labeled with a fluorescent quenching dye that quenches fluorescence upon interaction with guanine.

Citation Information

Patent Citations

  • Formation of forsterite insulating coated film on grain oriented silicon steel sheet

    JP1987054085A

  • Bordetella detection assay

    JP2011500085A

  • Method of detecting bordetella pertussis

    JP2014230511A

  • Oligonucleotide probe for detecting norovirus g1 type

    JP2018108054A

  • Oligonucleotide probe for detecting norovirus g2 type

    JP2018108055A